Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ05105 in Glucocorticoid-Refractory aGVHD
NCT04941404Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rovadicitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2022; status: terminated.
02
Drugs
rovadicitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04941404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941404.